Alnylam Pharmaceuticals Quarterly Balance Sheet
NASDAQ: ALNYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alnylam Pharmaceuticals financial position
As of Jun 30, 2026, Alnylam Pharmaceuticals reported total assets of $5.56 billion, up 21.7% from a year earlier against total liabilities of $4.20 billion. Shareholders' equity stood at $1.35 billion, or 24.4% of assets. The company held $1.71 billion in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 3.05, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Alnylam Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 1.71B | — | 1.66B | 1.49B | 1.11B | 1.02B | 966.43M | 1.10B | 968.49M | 681.88M | 812.69M | 1.03B |
| Short-Term Investments | 1.60B | — | 1.25B | 1.23B | 1.74B | 1.61B | 1.72B | 1.67B | 1.65B | 1.68B | 1.62B | 1.36B |
| Receivables | 912.74M | — | 777.57M | 964.77M | 567.11M | 418.04M | 405.31M | 353.85M | 309.48M | 321.38M | 327.79M | 325.44M |
| Inventory | 97.11M | — | 82.72M | 75.38M | 71.69M | 65.58M | 78.51M | 75.99M | 83.98M | 93.99M | 89.15M | 95.77M |
| Total Current Assets | 4.62B | — | 4.05B | 3.95B | 3.64B | 3.27B | 3.30B | 3.36B | 3.17B | 2.99B | 2.98B | 2.99B |
| Property, Plant & Equipment | 554.14M | — | 513.15M | 501.75M | 499.79M | 498.68M | 502.78M | 507.00M | 517.16M | 523.46M | 526.06M | 525.59M |
| Total Assets | 5.56B | — | 4.97B | 4.85B | 4.57B | 4.21B | 4.24B | 4.21B | 4.01B | 3.82B | 3.83B | 3.84B |
| Accounts Payable | 108.02M | — | 115.72M | 117.59M | 102.39M | 97.40M | 88.42M | 70.81M | 73.98M | 78.15M | 55.52M | 73.84M |
| Total Current Liabilities | 1.51B | — | 1.47B | 1.56B | 1.30B | 1.08B | 1.19B | 1.22B | 1.06B | 941.71M | 967.79M | 949.78M |
| Total Liabilities | 4.20B | — | 4.18B | 4.62B | 4.32B | 4.10B | 4.17B | 4.17B | 4.01B | 4.04B | 4.05B | 4.00B |
| Shareholders' Equity | 1.35B | 1.08B | 789.18M | 233.89M | 555.35M | 426.14M | 67.09M | 32.35M | -3.07M | -219.27M | -220.64M | -165.87M |
| Retained Earnings | -6.33B | — | -6.70B | -7.16B | -7.41B | -7.35B | -7.29B | -7.20B | -7.09B | -7.08B | -7.01B | -6.87B |
| Net Cash (Debt) | 3.31B | — | 2.91B | 2.72B | 2.86B | 2.63B | 2.69B | 2.77B | 2.61B | 2.36B | 2.43B | 2.40B |
| Shares Outstanding | 133.73M | — | 132.38M | 131.79M | 130.98M | 130.31M | 129.29M | 128.84M | 128.02M | 126.46M | 125.79M | 125.45M |
This table shows 12 quarterly periods of Alnylam Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ALNY's reporting calendar. What is a balance sheet?